Theseus begins phase II Apomate trial:
This article was originally published in Clinica
Executive Summary
North American Scientific's (NAS) subsidiary, Theseus Imaging, has begun a US, phase II clinical study of its nuclear imaging agent, Apomate, for assessing a patient's response to chemotherapy (see Clinica No 952, p 16). The trial will include patients with breast cancer, lung cancer and lymphoma, says NAS of Chatsworth, California.